Our study also revealed new cancer types harbouring known fusions (for example, BRAF fusion in rectal adenocarcinoma, FGFR3 fusion in prostate adenocarcinoma, RET fusions in colon adenocarcinoma and invasive breast carcinoma, EGFR–SEPT14 in low-grade glioma, and so on). This evidence concerns the gene FGFR3 and invasive breast carcinoma.